Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
DROP in Breakout Mode! :))
Our boy Tiger just moved from #18 to #6 on the world leaderboard... Great momentum for the Masters.
http://espn.go.com/golf/story/_/id/7736696/say-hello-new-tiger-woods-win-bay-hill
Solid win. Good timing. Sure hope they can capitalize and deliver.
Yorkshire, why do you think multiple launches ?
Good question... My guess is that the new guy will have a significant role to play:
http://ir.stockpr.com/fusescience/board-of-directors
R. Douglas Armstrong, Ph.D., has over 25 years of life science industry business and finance experience, with emphasis on early stage and emerging growth life science companies. Dr. Armstrong is a seasoned and diverse life science operational and banking executive, who served as the CEO of TyraTech from December 2006 to early 2010 and the CEO of Aastrom Biosciences (where he was also Chairman) from 1991 to 2006, leading both through initial public offerings. He specializes in development and implementation of capital strategies having personally led over $300 million in capital raises through a variety of public, PIPE and other structured deals, including strategic partnering transactions. Since July 2011, Dr. Armstrong has served as a member of the senior management of Tekesta Capital Partners, a division of WestPark Capital, Inc., and since 2010, as a founding partner and President of Auxol Capital, LLC, a life science investment fund. From February 2010 to July 2011, Dr. Douglas served as Senior Managing Director of Corporate Finance for LifeTech Capital, a division of Aurora Capital, LLC. Dr. Armstrong also served as a staff scientist for The Burnham Institute (La Jolla Cancer Research Institute) from 1987 to 1991, and as Assistant Professor, Department of Pharmacology and Cancer Research Institute at the University of California from 1983 to 1987. Dr. Armstrong holds a Ph.D. degree in Pharmacology from the Medical College of Virginia and a BA degree in Chemistry from the University of Richmond.
Tekesta Capital Partners: http://www.wpcapital.com/tekesta.html
Auxol Capital, LLC: http://www.onemedplace.com/network/list/cid/15027/
Between the two sources above, I would say that Fuse is well positioned for additional capital at more favorable terms than their current source (National Securities Corp: http://www.NationalSecurities.com/)
Our boy Tiger is on the prowel: http://www.heraldsun.com.au/sport/tiger-hits-form-in-time-for-masters/story-e6frf9if-1226308855429
No kidding ... very worrisome indeed
Looks like the chart is primed for a breakout... http://stockcharts.com/freecharts/gallery.html?DROP
Looks like our boy tiger is too :) http://timesofindia.indiatimes.com/sports/golf/top-stories/Tiger-Woods-looks-solid-in-return-at-Tavistock-Cup/articleshow/12335966.cms
Did Tiger use Enerjel for his recovery? ... If he wins, Fuse has an excellent opportunity to capitalize ...
We should counter-sue ! :) ...
Very true... And after the whole Michael Vick thing back last summer, Fuse might take this as a chance to strike back ... Seems Fuse has the upper hand to showcase how unique their product platform is.
not even the same name... EnerGel vs EnerJel ...
It would be great to see an uptrend in the coming weeks. With the April Masters around the corner and the Foster-Ortiz videos pending release, we could get some momentum. Another green day or two and we're in breakout mode. Fingers crossed :)
Contacted IR today: mentioned social media outlet 'mashable' as a potential portal to increase awareness. They were thankful of the referral. Figured that its more productive to help the cause. If anyone has other outlets in mind, pass them along to IR ...
Couldnt agree with you more! Expecting big things with this one :)
looks like funding won't be a problem:) http://www.wpcapital.com/tekesta.html
Well said! Thx
I hear ya. Fuse seems to be on to something big. The Mission deal is a huge vote of confidence in the technology. More deals to come soon. Momentum building. Charts are primed. just need the right catalyst and boom :)
From the 10K:
Fuse Science has developed and continues to advance, in concert with its scientific team, sublingual, transdermal delivery systems for bioactives that can effectively encapsulate and charge many varying molecules in order to produce complete product formulations which can bypass the GI tract and enter the blood stream directly. The delivery technology is comprised of proprietary encapsulation vesicles and ion exchange permeation enhancers. This technology utilizes a gradient across the mucosa membrane to help deliver the bioactive more efficiently through the mucosa.
Additionally, Fuse Science is in the process of designing and developing small hand held devices, in collaboration with our scientific team. These devices can conveniently deposit bioactives to the sublingual and buccal regions in the mouth and are very compatible with oral physiology, analogous to the common toothbrush. Our work further extends into transdermal applications with similar convenience and design principles. These devices are metered to deliver the needed dose of a given bioactive as applicable. By utilizing the skin’s innate bioelectric signaling system coupled with our iontopheritic delivery vehicle, we expect to be able to deliver bioactives efficaciously through both the dermal and buccal mucosal.
Seems that Fuse and Mission both have a lot to gain from this new partnership. A lot of synergy between the two.
"Fuse Science is a company with a dual track strategy for commercializing its delivery technology and systems that is expected to position the company for significant growth. The first strategy is to offer category exclusivity licensing opportunities to existing brands which will enhance brand differentiation and the second is accelerating distribution of the company's Powered By Fuse!™ performance products, by leveraging relationships such as Mission's retail network. These agreements with Mission are the latest in a series of anticipated distribution and partnership deals for Fuse Science"
http://ih.advfn.com/p.php?pid=nmona&article=51369655&symbol=DROP
I agree. tiger is brand ambassador. That is kind of sort of a BIG DEAL for Fuse and shareholders. He's not only an endorsement partner, he is BRAND AMBASSADOR. That being said, If he rocks house and gets the buzz going around him, Fuse has an easy platform to push their products.
No way, they don't stand a chance against Fuse. Look at their marketing. The delivery system is way too similar to smoking a joint. Basically an inhaler. Can you imagine pro-athletes puffing on these things before a big game... not unless they wanna look like crackheads.
http://abcnews.go.com/US/t/video/aero-shot-pure-caffeine-inhaler-officials-warn-of-kids-abusing-drug-french-device-health-15221804
Very true. But if they can execute the business plan as outlined in the 10K, their warrants and options will make them all very rich. The salaries pay the bills and keeps things in place. But the warrants/options are the real payoff if things go well. As shareholders, we get paid if they get paid. Warrants/Options are only valuable if share price appreciates. From how they've structure things, everyone involved has incentive to make Fuse run ... It doesn't get any better than that :S
Exactly. Top notch management needs to be paid. If they can get their business plan done and generate revenue, I would say that they kept dilution to a minimum. Naturally if fuse blows-up up big time, the salaries outlined wont matter as they'll be rolling in the multi-millions in revenue. what people that are cynical don't acknowledge is that Fuse has an ambitious business plan to go global. What may seem like slow progress may be misleading because we have no idea what's been happening in the background. For all we know, a pipeline for global distribution and/or pharma licensing may already be in place. They approached Tiger in July and announced in Nov. Clearly this group likes to do the legwork before material announcements. Regardless, based on the 10K, we're getting closer.
Sure seems that way! Can't wait for March Madess ;S
I also think that big news is coming in march. They've had enough time to get things lined up and have been making significant progress to that effect. March would be a perfect time to introduce the Drops and hit the commercialization phase full steam. Would imagine securing a global distribution channel has been a top priority. Would also imagine that syncing an aggressive marketing plan with the upcoming commercialization phase alongside pharma lisencing efforts is why they brought in the new VP's full-time. A lot of key developments being made and alot of ground work being laid out. Stock is quietly being accumulated now as well and is primed for a breakout.
Totally agree. Todays news is a primer of things to come.
Good to hear. The stage is being set for big things.
Something might be brewing. The chart is primed for a move. We're at November levels with lower volume. Any material announcement and boom! :))
I disagree. As a shareholder, I've communicated with the company and am assured that things are moving along as planned. The company has highlighted many material events in the pipeline within the former half of 2012 in the recent 10K filing. They moved to the new office as of Feb 1st, as in yesterday. It's only been a month since soft launch of first product via e-commerce route. Global distribution and product line expansion is set to launch sometime within the next six months. Enerjel e-commerce was just a intro/teaser. The main event is the full-blown global mult-product launch. The time from now till then is prep time. Going global is no small task. Daily announcements are not necessary, esp for longs.
The recent aliance with Tim Grover sure gives Fuse Science access to alot of talent in the NBA:
http://www.attackathletics.com/clients/
Allen, Tony
Arenas, Gilbert
Azubuike, Kelenna
Banks, Marcus
Barkley, Charles
Beverly, Patrick
Boozer, Carlos
Brand, Elton
Brown, Andre
Brown, Derrick
Bryant, Kobe
Budinger, Chase
Butler, Caron
Bynum, Will
Curry, Eddy
Deahl, David
Deng, Luol
Diop, DeSagana
Douglas-Roberts, Chris
Duhon, Chris
Evans, Jeremy
Felton, Raymond
Finley, Michael
Flynn, Jonny
Frye, Channing
Hardaway, Tim
Harris, Devin
Harper, Ron
Head, Luther
Hill, Jordan
Howard, Dwight
Howard, Juwan
Hughes, Larry
Hunter, Steven
Iguodala, Andre
Johnson, Wesley
Jordan, Michael
Kaman, Chris
Livingston, Shaun
Maggette, Corey
Marion, Shawn
Mason, Roger
Mayo, OJ
McGrady, Tracy
McNabb, Donovan
Miles, Darius
Mohammed, Nazr
O'Neal, Jermaine
Oakley, Charles
Olajuwon, Hakeem
Pargo, Jannero
Parker, Anthony
Pierce, Paul
Pippen, Scottie
Posey, James
Richardson, Quentin
Rodriguez, Alex
Rolle, Magnum
Simmons, Bobby
Solomon, Will
Stackhouse, Jerry
Steinbach, Eric
Thompson, Jason
Wade, Dwyane
Walker, Antoine
Walker, Bill
Warrick, Hakim
Wright, Dorell
The discussion is not whether they will dilute, it's whether they will dilute significantly. We just launched first product a few weeks ago, where exactly do you expect them to pull in operating funds in the immediate moment if not through selling a bit of shares? The commercialization phase and product expansion-licensing phase is within arms reach. To think that the company will not generate revenue within the next 6-12 months is a bit absurd considering that they will be selling product extensively during this time and have followed their business plan to a tee thus far. The 12M needed is over 18 months. The discussion should be about whether the company can generate the needed funds through its business model. It was merely pointed out that they could have unloaded shares at recent highs of 1.25 and .75 before that if the plan was to get the 12M just through selling shares. You brought up valid concerns but the topic of dilution is not as much of a concern as it has been made out to be. The next high could very well be 1.50 and maybe even around the corner if Tiger and company keep the momentum going from last year. Current stagnation in share price has been brought on by a number of factors. You seem like a well versed trader. There comes a point where one has to do the DD and either believe in a company or not.
Actually, I think the most recent 10K highlights that they do not intend to dilute to raise the 12M needed over the next 18 months. Instead they indicated an aggressive commercialization phase commencing in the first half of 2012 with an expansion of enerjel from launch phase to global distribution phase in addition to the introduction of the drops (hydroFuse, powerFuse, and nutriFuse). They also said that licensing efforts will be targeted simultaneously during this commercialization phase. Also, they indicated potential alliances to accelerate the expansion process. Considering we're going into month 2 of the first six months of 2012, I would imagine that the commercialization-licensing-marketing will hit full throttle soon in order to make this next 'phase' as productive and profitable as possible. Would also imagine that the revenue generated will pipeline the needed expansion funds without significantly diluting shareprice. Time will tell how Fuse does. So far so good :)
IR Reply...
PD,
Thank you very much for the email and we appreciate your support as a shareholder.
We agree that there are many fertile markets for our technology and products, the examples given below are certainly attractive candidates. However, in the process of building and growing our company, we have to maintain focus and be deliberate as we enter new markets.
As we continue to get our legs underneath us and educate the markets as to our technology and ultimately our diverse application opportunities, these and other markets will be ripe for us to enter. However, that doesn't mean that we are not introducing ourselves and discussing possible applications with these other channels currently. We are not only looking at additional athletic industry opportunities, but also opportunities within the health and medical markets as well.
This is an exciting time for Fuse Science and we must be responsible in how we grow the company and form new partnerships/relationships so that the seeds we sow today, become ripe and benefit shareholders in the future.
Sincerely,
Fuse Science, Inc.
ME...
Hi there,
Being a long-standing shareholder, I'm just wondering what company thoughts are w.r.t. the below comments from two posters on Fuse Science's facebook 01/13/12 Q&A post:
"Week after week, month after month, the UFC continues to be the leader in sponsoring game changing products for athletes. Their events are not seasonal and are repeatedly played on tv. With this in mind you may want to put a considerable amount of effort with a spokesperson like Randy "The Natural" Couture (referring to your all natural ingredients) or pick one of the top performers like John "Bones" Jones. Just my opinion."
"You need to contact Dana White at the UFC and try to get John Jones or Georges St. Pierre as spokes people that are powered by Fuse. It could be a game changer for your company!"
Also, what about the nba and/or ncaa ? I would imagine that an expansive plan in already thought out. Just wondering whether we will see exposure of other sports in addition to ones already being represented through the endorsement partners.
Thanks,
-PD